HUTCHMED (China) (HMDCF) EPS (Basic) (2015 - 2021)

HUTCHMED (China)'s (HMDCF) quarterly EPS (Basic) came in at -$1.49 in Q4 2021, down 221.74% quarter-over-quarter from $1.22 in Q3 2021.

Analysis

HUTCHMED (China) (HMDCF) EPS (Basic) (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported EPS (Basic) for 6 consecutive years, with -$1.49 the latest figure, recorded in Q4 2021.

On a quarterly basis, EPS (Basic) changed N/A year-over-year to -$1.49 in Q4 2021; TTM through Dec 2021 was $0.23, a N/A change from a year earlier, with the FY2025 full-year figure at $3.28, up 153010.58% from the prior year.
EPS (Basic) was -$1.49 for Q4 2021 at HUTCHMED (China), down from $1.22 in the prior quarter.
Over five years, EPS (Basic) peaked at $1.22 in Q3 2021 and troughed at -$1.49 in Q4 2021.
A 4-year average of $0.03 and a median of $0.17 in 2018 frame the typical range for EPS (Basic).
The widest YoY moves for EPS (Basic): up 239.95% in 2019, down 348.88% in 2019.
Over 4 years, EPS (Basic) stood at $0.17 in 2018, then plunged by 270.5% to -$0.28 in 2019, then jumped by 161.02% to $0.17 in 2020, then sank by 959.31% to -$1.49 in 2021.
The last three EPS (Basic) figures came in at -$1.49 (Q4 2021), $1.22 (Q3 2021), and $0.44 (Q2 2021), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Amgen	212.35 Bn	198.36 Bn	7.24 Bn	4.40
2	Gilead Sciences	181.19 Bn	178.01 Bn	6.22 Bn	-8.44
3	Vertex Pharmaceuticals	132.48 Bn	124.62 Bn	2.84 Bn	4.34
4	Regeneron Pharmaceuticals	82.59 Bn	74.60 Bn	3.93 Bn	12.62
5	Argenx Se	61.45 Bn	56.27 Bn	1.37 Bn	7.70
6	Moderna	54.89 Bn	49.75 Bn	52.00 Mn	-1.96
7	Alnylam Pharmaceuticals	34.21 Bn	30.90 Bn	992.69 Mn	1.23
8	Biogen	31.38 Bn	30.10 Bn	1.96 Bn	0.66
9	Roivant Sciences	29.81 Bn	29.81 Bn	1.16 Mn	-0.40
10	HUTCHMED (China)	376.85 Mn	391.04 Mn	-	-

Historic Data

Download Data